{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:55:34Z","timestamp":1769122534698,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Few studies have investigated the clinical benefit of the long-term use of tolvaptan (TLV) for heart failure (HF). This study evaluated the long-term prognosis of patients administered TLV for\u2009&gt;\u20091\u00a0year among patients who had HF with preserved ejection fraction (HFpEF) and those who had HF with reduced ejection fraction (HFrEF). Overall, 591 consecutive patients were admitted to our hospital and administered TLV for HF between 2011 and 2018. We retrospectively enrolled 147 patients who were administered TLV for\u2009&gt;\u20091\u00a0year. We divided them into the HFpEF group (<jats:italic>n<\/jats:italic>\u2009=\u200977, 52.4%) and the HFrEF group (<jats:italic>n<\/jats:italic>\u2009=\u200970; 47.6%). Their clinical backgrounds and long-term prognosis were examined. Compared with the patients in the HFrEF group, the patients in the HFpEF group were significantly older and included more women. Moreover, the HFpEF group showed significantly lower all-cause mortality (38.6% vs. 24.7%; log-rank, <jats:italic>P<\/jats:italic>\u2009=\u20090.014) and cardiovascular mortality during the average 2.7-year follow-up. Univariate analysis revealed that all-cause mortality was correlated with male sex, HFpEF, and changes in serum creatinine levels from baseline. Multivariate analysis revealed that HFpEF was an independent influencing factor for all-cause mortality (hazard ratio, 0.44; 95% confidence interval, 0.23\u20130.86; <jats:italic>P<\/jats:italic>\u2009=\u20090.017). Long-term administration of TLV may be more beneficial for HFpEF than for HFrEF.<\/jats:p>","DOI":"10.1007\/s00380-021-01957-1","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T07:15:19Z","timestamp":1634195719000},"page":"574-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical features and long-term prognosis of patients with congestive heart failure taking tolvaptan: a comparison of patients with preserved and reduced left ventricular ejection fraction"],"prefix":"10.1007","volume":"37","author":[{"given":"Toshiki","family":"Seki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-7641","authenticated-orcid":false,"given":"Yoshiaki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukichi","family":"Tokita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-ki","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"1957_CR1","first-page":"e139","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW (2020) Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 141:e139\u2013e596","journal-title":"Circulation"},{"key":"1957_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1253\/circj.72.489","volume":"72","author":"Y Okura","year":"2008","unstructured":"Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, Suzuki K, Tanabe N, Kodama M, Aizawa Y (2008) Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J 72:489\u2013491","journal-title":"Circ J"},{"key":"1957_CR3","volume":"7","author":"Y Shiraishi","year":"2018","unstructured":"Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T, Matsue Y (2018) 9-year trend in the management of acute heart failure in japan: a report from the national consortium of acute heart failure registries. J Am Heart Assoc 7:e008687","journal-title":"J Am Heart Assoc"},{"key":"1957_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1253\/circj.CJ-18-1087","volume":"83","author":"K Akita","year":"2019","unstructured":"Akita K, Kohno T, Kohsaka S, Shiraishi Y, Nagatomo Y, Goda A, Mizuno A, Sujino Y, Fukuda K, Yoshikawa T (2019) Prognostic impact of previous hospitalization in acute heart failure patients. Circ J 83:1261\u20131268","journal-title":"Circ J"},{"key":"1957_CR5","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","volume":"371","author":"G Decaux","year":"2008","unstructured":"Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624\u20131632","journal-title":"Lancet"},{"key":"1957_CR6","doi-asserted-by":"publisher","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290:F273-278","journal-title":"Am J Physiol Renal Physiol"},{"key":"1957_CR7","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297:1332\u20131343","journal-title":"JAMA"},{"key":"1957_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319\u20131331","journal-title":"JAMA"},{"key":"1957_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","volume":"285","author":"PA McKee","year":"1971","unstructured":"McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441\u20131446","journal-title":"N Engl J Med"},{"key":"1957_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R (2013) Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2013association between non-responders and chronic kidney disease. Circ J 77:397\u2013404","journal-title":"Circ J"},{"issue":"Suppl 1","key":"1957_CR11","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1007\/s10557-011-6348-y","volume":"25","author":"M Fukunami","year":"2011","unstructured":"Fukunami M, Matsuzaki M, Hori M, Izumi T (2011) Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study. Cardiovasc Drugs Ther 25(Suppl 1):S47-56","journal-title":"Cardiovasc Drugs Ther"},{"key":"1957_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2017","unstructured":"Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Shinagawa H, Ako J, Izumi T (2017) Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: results from the K-STAR study. Circ J 82:159\u2013167","journal-title":"Circ J"},{"key":"1957_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s00380-020-01753-3","volume":"36","author":"Y Morita","year":"2021","unstructured":"Morita Y, Endo A, Kagawa Y, Yamaguchi K, Sato H, Ouchi T, Watanabe N, Tanabe K (2021) Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure. Heart Vessels 36:836\u2013843","journal-title":"Heart Vessels"},{"key":"1957_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1536\/ihj.16-023","volume":"57","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kinugawa K (2016) Tolvaptan improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction. Int Heart J 57:600\u2013606","journal-title":"Int Heart J"},{"key":"1957_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1536\/ihj.17-099","volume":"59","author":"M Nakamura","year":"2018","unstructured":"Nakamura M, Sunagawa O, Kinugawa K (2018) Tolvaptan improves prognosis in responders with acute decompensated heart failure by reducing the dose of loop diuretics. Int Heart J 59:87\u201393","journal-title":"Int Heart J"},{"key":"1957_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455\u2013469","journal-title":"Eur Heart J"},{"key":"1957_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ehf2.12088","volume":"3","author":"K Jujo","year":"2016","unstructured":"Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3:177\u2013188","journal-title":"ESC Heart Fail"},{"key":"1957_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","volume":"50","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Bramer SL, Bricmont P, Zimmer CA (2007) Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 50:213\u2013222","journal-title":"J Cardiovasc Pharmacol"},{"key":"1957_CR19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1253\/circj.CJ-17-0554","volume":"81","author":"Y Uemura","year":"2017","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Imai R, Ozaki Y, Watanabe T, Teraoka T, Watarai M, Murohara T (2017) Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J 81:1736\u20131738","journal-title":"Circ J"},{"key":"1957_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00380-015-0775-9","volume":"31","author":"Y Uemura","year":"2016","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Mitsuda T, Miura A, Imai R, Iwamiya S, Ozaki Y, Kato T, Miura T, Watarai M, Murohara T (2016) Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 31:1643\u20131649","journal-title":"Heart Vessels"},{"key":"1957_CR21","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00380-021-01801-6","volume":"36","author":"K Nakao","year":"2021","unstructured":"Nakao K, Horio T, Yoshimura R, Fujiwara R, Matsuoka Y, Yokouchi G, Nakamura H, Sakamoto Y, Fujimoto K, Izumiya Y, Yoshiyama M, Kasayuki N (2021) Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure. Heart Vessels 36:1175\u20131182","journal-title":"Heart Vessels"},{"key":"1957_CR22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1253\/circj.CJ-09-0254","volume":"73","author":"M Tsuchihashi-Makaya","year":"2009","unstructured":"Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, Kato N, Takeshita A, Tsutsui H (2009) Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73:1893\u20131900","journal-title":"Circ J"},{"key":"1957_CR23","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC (2017) Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 70:2476\u20132486","journal-title":"J Am Coll Cardiol"},{"key":"1957_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18773\/austprescr.2020.006","volume":"43","author":"E Gard","year":"2020","unstructured":"Gard E, Nanayakkara S, Kaye D, Gibbs H (2020) Management of heart failure with preserved ejection fraction. Aust Prescr 43:12\u201317","journal-title":"Aust Prescr"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-021-01957-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-021-01957-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-021-01957-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T03:04:01Z","timestamp":1647054241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-021-01957-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1007\/s00380-021-01957-1","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Nippon Medical School Hospital (B-2020-226).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The need for patient consent because of the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}